CATXNYSEPharmaceutical PreparationsFiscal year ends December 31

Perspective Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$2.19+0.02 (+0.92%)

Close on Oct 19, 2026

Market cap: $264.23M
P/E (TTM): –
Dividend yield: –

Perspective Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2022 2022-06-30	Q3 2022 2022-03-31	Q2 2022 2021-12-31	Q1 2022 2021-09-30	Q4 2021 2021-06-30	Q3 2021 2021-03-31	Q2 2021 2020-12-31	Q1 2021 2020-09-30	Q4 2020 2020-06-30	Q3 2020 2020-03-31	Q2 2020 2019-12-31	Q1 2020 2019-09-30	Q4 2019 2019-06-30	Q3 2019 2019-03-31	Q2 2019 2018-12-31	Q1 2019 2018-09-30	Q4 2018 2018-06-30	Q3 2018 2018-03-31	Q2 2018 2017-12-31	Q1 2018 2017-09-30	Q4 2017 2017-06-30	Q3 2017 2017-03-31	Q2 2017 2016-12-31	Q1 2017 2016-09-30	Q4 2016 2016-06-30	Q3 2016 2016-03-31	Q2 2016 2015-12-31	Q1 2016 2015-09-30	Q4 2015 2015-06-30	Q3 2015 2015-03-31
Depreciation & Amortization	1.14	1.13	1.01	0.78	0.73	0.73	0.71	0.67	0.57	0.36	0.08	0.07	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.02	0.02	0.02	0.02	0.06	0.14	0.14	0.14	0.14	0.13
Stock-Based Compensation	3.05	2.55	2.31	2.16	2.40	2.10	2.06	1.95	0.59	0.66	0.15	0.16	0.18	0.60	0.13	0.09	0.08	0.09	0.22	0.09	0.09	0.09	0.15	0.08	0.10	0.09	0.09	0.08	0.08	0.09	0.21	0.04	0.05	0.07	0.06	0.17	0.03	0.03	0.14	0.02
Deferred Income Taxes	0	–	–	–	0	–	-2.10	0	0	0	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Cash Items	-0.04	-0.08	0.23	-0.01	-0.08	-0.14	0.11	-0.07	-0.11	-0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	-0.21	-0.05	0.17	0.05	-0.15	0.04	0.22	-0.15	0.81	0.17	0.53	-0.49	0.26	0.11	0.01	-0.28	0.02	0.29	0.10	-0.74	0.11	-0.37	-0.04	-0.01	-0.04	0.12	-0.22	0.01	-0.24	-0.02	0.07	-0.23	-0.05	0.03	0.28	0.09	0.16	-0.08	-0.01	-0.24
Change in Inventory	–	–	–	0	0	0	–	0	-0.02	0.03	-2.00	0.08	0.04	-0.80	-0.13	-0.06	-0.02	-0.06	-0.08	-0.03	-0.03	0.04	0.09	-0.02	0.04	0.01	0.04	0.02	0.01	-0.04	0.04	0.08	0.02	-0.04	0.10	-0.05	-0.02	-0.06	-0.04	-0.05
Change in Accounts Payable	0.63	-4.21	-0.85	5.54	-2.84	-1.71	-13	16	0.12	-0.88	0.20	-0.08	0.08	0.04	-0.26	0.50	-0.26	0.11	-0.29	0.31	-0.35	0.30	-0.32	-0.20	0.03	-0.22	0.67	0.15	-0.23	0.18	0.12	0.20	-0.18	-0.12	-0.12	0.05	0.27	-0.09	0.06	-0.05
Change in Unearned Revenue	0	0	0	0	0	-1.40	0	0	0	28	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Cash Flow	-21	-31	-25	-16	-20	-22	-27	3.37	-8.90	14	-2.89	-1.42	-1.31	-2.08	-1.12	-0.62	-0.76	-0.34	-0.85	-0.86	-1.28	-0.65	-0.99	-1.34	-1.11	-1.61	-1.45	-1.08	-1.52	-1.66	-1.21	-1.49	-1.66	-1.35	-1.21	-0.76	-0.81	-1.11	-0.63	-1.13
Capital Expenditures	-14	-6.86	-5.08	-1.99	-1.03	-4.66	-15	-30	-1.02	-9.07	-0.11	-0.03	-0.08	-0.05	-0.12	-0.09	-0.06	-0.11	-0.03	-0.04	-0.11	-0.10	-0.09	-0.13	-0.11	-0.11	-0.11	-0.08	-0.10	-0.05	-0.26	-0.05	-0.09	-0.15	-0.22	-0.23	-0.03	0.00	-0.06	-0.03
Sale of Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	0	–	–	–	0	–	–	–	–	–	–	–	0.01	0.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Purchase of Investments	-36	-150	-21	-32	-44	-23	-165	0	-41	-38	–	–	0	0	–	–	–	–	–	–	–	–	6.42	-2.88	-1.51	-6.75	0	-0.50	-0.25	-3.30	-0.03	-0.03	-0.03	-0.03	-6.21	-0.08	-0.08	-6.11	-11	-4.10
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-4.08	5.21	3.84	0.58	1.33	1.08	0.83	3.04	2.30	0	0	0	5.93	6.03	0	3.53	5.84	5.02
Investing Cash Flow	15	-110	29	14	4.26	-5.57	-139	-30	-3.30	-47	-0.12	-0.03	-0.08	-0.05	-0.14	-0.10	-0.06	-0.11	-0.04	-0.04	-0.11	-0.10	2.24	2.21	2.25	-6.29	1.20	0.49	0.48	-0.32	2.05	-0.08	-0.12	-0.33	5.65	5.77	-0.09	-2.58	4.70	0.88
Stock Issued	–	–	–	–	–	–	–	–	–	–	0	0	–	–	–	48	–	–	–	–	–	–	–	-0.01	-0.11	7.49	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	0.15	164	-0.01	0.21	0.13	9.97	0.35	0.63	122	166	0	0	0.06	0	0.24	56	–	–	0.87	0.13	–	–	0.01	-0.01	-0.12	7.49	0.48	0	–	–	0	0	-0.01	0	0	0.00	-0.01	0.05	0.08	0.00
Net Change in Cash	-5.48	23	3.87	-2.09	-16	-17	-165	-26	110	133	-3.01	-1.45	-1.34	-2.14	-1.01	55	7.65	-0.45	-0.01	-0.78	-1.40	-0.75	1.27	0.86	1.01	-0.41	0.24	-0.59	-1.01	-1.98	0.83	-1.57	-1.79	-1.68	4.45	5.02	-0.91	-3.64	4.15	-0.26
Free Cash Flow	-35	-38	-30	-18	-21	-26	-41	-26	-9.92	4.78	-3.00	-1.45	-1.39	-2.14	-1.23	-0.71	-0.82	-0.45	-0.87	-0.91	-1.38	-0.75	-1.08	-1.47	-1.23	-1.73	-1.55	-1.16	-1.62	-1.72	-1.47	-1.54	-1.75	-1.50	-1.43	-0.98	-0.84	-1.11	-0.68	-1.16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -41.4%

Financial strength

Current ratio: 6.61
Debt to equity: 0.00
Debt to assets: 0.4%
Cash to current liabilities: 132.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.82
Dividend yield: –